| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/27/2004 | US20040101482 Medicaments |
| 05/27/2004 | US20040101481 Inhalation therapy |
| 05/27/2004 | US20040098847 Funerary container made of paper material, and assembly device employed therein |
| 05/27/2004 | DE10253282A1 Treatment of chronic obstructive pulmonary disease, using new or known N-substituted 2-amino-1-(benz-(1,4)-oxazin-3-on-8-yl)-ethanol derivative beta-mimetic agents, suitable for once-daily administration |
| 05/27/2004 | DE10253220A1 New 2-(N-phenylalkyl-amino)-1-phenyl-ethanol derivatives, are beta-adrenergic agents especially useful for treating inflammatory and obstructive respiratory diseases such as asthma or COPD |
| 05/27/2004 | DE10253111A1 Powdered formulation used e.g. as food additive or pharmaceutical for preventing arteriosclerosis and hyperlipemia, contains phytosterol |
| 05/27/2004 | DE10252478A1 Treating fibromyalgia syndrome and chronic fatigue syndrome, using tetradecenoic acid or its derivative, preferably cetyl ester |
| 05/27/2004 | CA2765093A1 Bicyclic-substituted amines as histamine-3 receptor ligands |
| 05/27/2004 | CA2513493A1 Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds |
| 05/27/2004 | CA2505951A1 Oral testosterone delivery system with improved sustained release |
| 05/27/2004 | CA2505876A1 Novel parp inhibitors |
| 05/27/2004 | CA2505861A1 Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or bucally |
| 05/27/2004 | CA2505557A1 Mucin synthesis inhibitors |
| 05/27/2004 | CA2505514A1 Treatment of amyotrophic lateral sclerosis with nimesulide |
| 05/27/2004 | CA2505478A1 Antioxidant pharmaceutical compound, method for producing polypeptide and method of cure |
| 05/27/2004 | CA2505373A1 Methods of using vitamin d compounds in the treatment of myelodysplastic syndromes |
| 05/27/2004 | CA2505372A1 Fused heterocyclic compounds |
| 05/27/2004 | CA2505131A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| 05/27/2004 | CA2505118A1 Calmodulin independent activation of nitric oxide synthase by nadph analogs |
| 05/27/2004 | CA2505092A1 Lysine mixture and apparatus and method for administering lysine |
| 05/27/2004 | CA2505088A1 Water soluble monomers and polymers for protecting subtrates from ultraviolet light |
| 05/27/2004 | CA2505003A1 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
| 05/27/2004 | CA2504959A1 Substituted alkyl-pyridazinones for the treatment of memory and learning malfunctions |
| 05/27/2004 | CA2504916A1 Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| 05/27/2004 | CA2504903A1 Method for identifying risk of melanoma and treatments thereof |
| 05/27/2004 | CA2504878A1 Cholesterol absorption inhibitors for the treatment of demyelination |
| 05/27/2004 | CA2504821A1 System and method for generating an amalgamated database |
| 05/27/2004 | CA2504807A1 Dermastick thickened ointment |
| 05/27/2004 | CA2504766A1 2-pyridone derivatives as inhibitors of neutrophile elastase |
| 05/27/2004 | CA2504737A1 Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
| 05/27/2004 | CA2504732A1 Polymorphs of bicifadine hydrochloride |
| 05/27/2004 | CA2504666A1 Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine |
| 05/27/2004 | CA2504611A1 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| 05/27/2004 | CA2504605A1 Treatment of chronic lymphocytic leukemia and prostate cancer with microrna mir15 |
| 05/27/2004 | CA2504460A1 Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases |
| 05/27/2004 | CA2504310A1 Method of treating sepsis-induced ards |
| 05/27/2004 | CA2504226A1 Histone deacetylase inhibitors for treating degenerative diseases of the eye |
| 05/27/2004 | CA2504200A1 The use of an anti-allergy agent and a steroid to treat allergic rhinitis |
| 05/27/2004 | CA2504197A1 Topical parasiticide formulations and methods of treatment |
| 05/27/2004 | CA2503644A1 Dietary supplement comprising parthenolide |
| 05/27/2004 | CA2503641A1 Compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms |
| 05/27/2004 | CA2503630A1 Improved formulations containing substituted imidazole derivatives |
| 05/27/2004 | CA2502427A1 Combination product for controlling insect pests |
| 05/27/2004 | CA2502363A1 Irrigation solution and method for inhibition of tumor cell adhesion, pain and inflammation |
| 05/27/2004 | CA2502190A1 Pyrimidine compounds |
| 05/27/2004 | CA2501932A1 Use of benzimidazole quinolinones for treating cancer |
| 05/27/2004 | CA2501077A1 Polysaccharide vaccine for staphylococcal infections |
| 05/27/2004 | CA2499463A1 Compositions and methods for prolonging survival of platelets |
| 05/27/2004 | CA2497268A1 Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
| 05/27/2004 | CA2492103A1 Flavin n-oxides: new anti-cancer agents and pathogen eradication agents |
| 05/26/2004 | EP1422234A2 Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone |
| 05/26/2004 | EP1422229A1 Porphyrin-metal complexes and oxygen infusions containing the same |
| 05/26/2004 | EP1422228A1 BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE |
| 05/26/2004 | EP1422225A1 Benzoisoselenazole derivatives with anti-inflammation, antivirus and anti-thrombosis activity and their use |
| 05/26/2004 | EP1422224A1 Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin |
| 05/26/2004 | EP1422219A1 Cyclic amine compound |
| 05/26/2004 | EP1422218A1 Antiviral agent |
| 05/26/2004 | EP1422217A2 Aminocyclohexyl ether compounds and uses thereof |
| 05/26/2004 | EP1421974A1 Carboxy methyl beta-1, 3 glucan containing ophthalmic solution |
| 05/26/2004 | EP1421955A1 Percutaneous absorption preparations |
| 05/26/2004 | EP1421953A1 Medicinal compositions containing angiotensin ii receptor antagonist |
| 05/26/2004 | EP1421952A1 Myocardial cell apoptosis inhibitors |
| 05/26/2004 | EP1421946A1 A pharmaceutical being used for treating hiv infection, the composition and uses thereof |
| 05/26/2004 | EP1421945A1 Bile acid absorbent/adsorbent |
| 05/26/2004 | EP1421943A1 Use of low-molecular-weight heparins for preventing and treating central nervous system trauma |
| 05/26/2004 | EP1421942A1 Use of glycyrrhizin and its derivatives as RANTES inducers |
| 05/26/2004 | EP1421941A1 Phospholipid derivatives having a polyhydroxylated aliphatic carbocycle |
| 05/26/2004 | EP1421940A1 Medical composition for external use for dermatosis |
| 05/26/2004 | EP1421939A1 Sustained release preparation of a macrolide compound like tacrolimus |
| 05/26/2004 | EP1421938A1 Antitumor agents and process for producing the same |
| 05/26/2004 | EP1421937A1 Use of amino acids for making medicines for treating insulin-resistance |
| 05/26/2004 | EP1421936A1 Potassium channel opener |
| 05/26/2004 | EP1421935A1 Thiourea carbonic anhydrase inhibitors and their use in treatment of glaucoma |
| 05/26/2004 | EP1421934A1 Remedial agent for arthrosis deformans |
| 05/26/2004 | EP1421933A1 Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus |
| 05/26/2004 | EP1421858A1 Use of medium chain triglycerides (MCT) for the nutritional optimisation of the lipid composition of a dietetic product for diabetics |
| 05/26/2004 | EP1421391A2 Sodium channel regulators and modulators |
| 05/26/2004 | EP1421384A2 Hprp4s as modifiers of the p53 pathway and methods of use |
| 05/26/2004 | EP1421377A2 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 05/26/2004 | EP1421222A2 Cell culture system for synthesis of infectious hepatitis c virus |
| 05/26/2004 | EP1421218A2 Model of autoimmune disease and methods for identifying agents against autoimmune disease |
| 05/26/2004 | EP1421214A2 Amplified oncogenes and their involvement in cancer |
| 05/26/2004 | EP1421198A2 Cell-based high-throughput screening methods |
| 05/26/2004 | EP1421190A2 Metabolic gene polynucleotides and polypeptides and uses thereof |
| 05/26/2004 | EP1421170A2 Therapeutic delivery compositions and methods of use thereof |
| 05/26/2004 | EP1421120A1 Hyperbranched amylopectin for use in methods for surgical or therapeutic treatment of mammals or in diagnostic methods, especially for use as a plasma volume expander |
| 05/26/2004 | EP1421118A1 A method for the treatment or prevention of bone erosion |
| 05/26/2004 | EP1421112A1 Novel serine protease |
| 05/26/2004 | EP1421111A2 Proteins associated with cell growth differentiation, and death |
| 05/26/2004 | EP1421110A2 Novel genetic products from ashbya gossypii, associated with the structure of the cell wall or the cytoskeleton |
| 05/26/2004 | EP1421105A1 Anti-cancer cyclopenta[g]quinazoline compounds |
| 05/26/2004 | EP1421101A2 P-glycoproteins and uses thereof |
| 05/26/2004 | EP1421099A1 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
| 05/26/2004 | EP1421093A1 Crystaline clindamycin free base |
| 05/26/2004 | EP1421092A1 Neutral glycosphingolipids and glycosyl-sphingosines and methods for isolating the same |
| 05/26/2004 | EP1421091A1 Saccharide sulfation methods |
| 05/26/2004 | EP1421089A1 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS |
| 05/26/2004 | EP1421088A1 4-thioxo-4,7-dihydro-thieno 2,3-b]pyridine-5-carbothioamides as antiviral agents |
| 05/26/2004 | EP1421087A1 Diazacycloalkanes as oxytocin agonists |
| 05/26/2004 | EP1421086A1 2-(AMINOMETHYL)-TETRAHYDRO-9-OXA-1,3-DIAZA-CYCLOPENTA a]NAPHTHALENYL DERIVATIVES WITH ANTIPSYCHOTIC ACTIVITY |